Avalon Trust Co increased its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 217.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,627 shares of the company’s stock after buying an additional 1,800 shares during the quarter. Avalon Trust Co’s holdings in Zoetis were worth $428,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Mission Wealth Management LP boosted its holdings in Zoetis by 2.0% during the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after buying an additional 59 shares in the last quarter. Hancock Whitney Corp lifted its holdings in Zoetis by 0.3% during the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC lifted its holdings in Zoetis by 3.5% during the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares in the last quarter. VeraBank N.A. lifted its holdings in Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after purchasing an additional 62 shares in the last quarter. Finally, Procyon Advisors LLC lifted its holdings in Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company’s stock.
Analysts Set New Price Targets
View Our Latest Research Report on Zoetis
Zoetis Price Performance
Zoetis stock opened at $161.33 on Friday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The stock has a market cap of $72.24 billion, a P/E ratio of 29.49, a PEG ratio of 2.78 and a beta of 0.94. The company has a 50-day moving average price of $166.82 and a 200 day moving average price of $176.15. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.
Zoetis Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.24%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is currently 36.56%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- Industrial Products Stocks Investing
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Roth IRA Calculator: Calculate Your Potential Returns
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Technology Stocks Explained: Here’s What to Know About Tech
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.